Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Inclusion Criteria

• Histologically confirmed invasive adenocarcinoma of the breast or inflammatory breast cancer, with an interval between definitive breast surgery and study registration of 0.2 mm, OR lymph node-negative patients with high-risk features
• Patients with HER2/neu positive or negative tumors (HER2 positivity must be documented by FISH positivity or IHC 3+).
• Patients who are to receive trastuzumab must have normal cardiac function (MUGA [cardiac ejection fraction >50%, or greater than or equal to the institutional lower limit of normal], or echocardiogram [ECHO] within institutional normal limits).
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
• Patients who are either chemotherapy naïve, or who have received prior chemotherapy >5 years ago.
• Patients with previous invasive cancers (including breast cancer) eligible only if treated >5 years prior to entering this study, and show no evidence of recurrent disease.
• Adequate bone marrow function
• Adequate liver function,
• Adequate renal function,
• Patients of childbearing potential must use an effective method of contraception that is acceptable to their study physician from the time of signing informed consent until at least 3 months after the last dose of protocol treatment, and must have a negative pre study serum pregnancy test.
• Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.
• MammoSite® brachytherapy radiation accepted when performed immediately following surgery and prior to receiving chemotherapy.
• Patients with bilateral, synchronous breast cancer, provided that one primary tumor meets the inclusion criteria.

Exclusion Criteria

• Patients who are pregnant or breastfeeding.
• M1 metastatic disease.
• Patients requiring neoadjuvant chemotherapy.
• Life expectancy of greater than 6 months.
• History of cardiac disease, with a New York Heart Association (NYHA) Class II or greater CHF
• Myocardial infarction (MI) or unstable angina in the past 12 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment, any history of stroke or transient ischemic attack at any time, clinically significant peripheral vascular disease, or evidence of a bleeding diathesis or coagulopathy.
• Any investigational agent within 30 days of receiving the first dose of study drug.
• Treatment with prior trastuzumab or bevacizumab therapy.
• Concurrent treatment with any other anti-cancer therapy is not permitted.
• History of significant psychiatric disorders.
• History of active, uncontrolled infection.
• A serious, non-healing wound, ulcer, or bone fracture.
• Any other diseases, metabolic dysfunction, findings from a physical examination, or clinical laboratory test results that give reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results or that renders the patient at high risk from treatment complications.